Mário Nôro Laço

Mário Nôro Laço

Auto-generated profile, based on publicly available information

Mário Nôro Laço

University of Coimbra

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2016 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
LNLuana Naia
Luana Naia
TRTatiana Rosado Rosenstock
Tatiana Rosado Rosenstock
AOAna M. Oliveira
Ana M. Oliveira
SOSofia I. Oliveira-Sousa
Sofia I. Oliveira-Sousa
GCGladys L. Caldeira
Gladys L. Caldeira
Ana Cristina Cristina RegoAna Cristina Cristina Rego
Ana Cristina Cristina Rego

20 May 2014 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
LNLuana Naia
Luana Naia
IFIldete Luísa Ferreira
Ildete Luísa Ferreira
Teresa Cunha-OliveiraTeresa Cunha-Oliveira
Teresa Cunha-Oliveira
Ana DuarteAna Duarte
Ana Duarte
MRMárcio Ribeiro
Márcio Ribeiro
Ana Cristina Cristina RegoAna Cristina Cristina Rego
Ana Cristina Cristina Rego

20 October 2011 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
MLMário N. Laço
Mário N. Laço
COCatarina R. Oliveira
Catarina R. Oliveira
HPHenry L. Paulson
Henry L. Paulson
Ana Cristina Cristina RegoAna Cristina Cristina Rego
Ana Cristina Cristina Rego


1 October 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
STSokol V. Todi
Sokol V. Todi
MLMario N. Laco
Mario N. Laco
BWBrett J. Winborn
Brett J. Winborn
STSue M. Travis
Sue M. Travis
HWHsiang M. Wen
Hsiang M. Wen
HPHenry L. Paulson
Henry L. Paulson
Ataxin-3, a deubiquitinating enzyme, is the disease protein in spinocerebellar ataxia type 3, one of many neurodegenerative disorders caused by polyglutamine expansion. Little is known about the cellular regulation of ataxin-3. This is an important issue, since growing evidence links disease protein context to pathogenesis in polyglutamine disorders. Expanded ataxin-3, for example, is more neurotoxic in fruit fly models when its active site cysteine is mutated (1). We therefore sought to determine the influence of ataxin-3 enzymatic activity on various cellular properties. Here we present evidence that the catalytic activity of ataxin-3 regulates its cellular turnover, ubiquitination, and subcellular distribution. Cellular protein levels of catalytically inactive ataxin-3 were much higher than those of active ataxin-3, in part reflecting slower degradation. In vitro studies revealed that inactive ataxin-3 was more slowly degraded by the proteasome and that this degradation occurred independent of ubiquitination. Slower degradation of inactive ataxin-3 correlated with reduced interaction with the proteasome shuttle protein, VCP/p97. Enzymatically active ataxin-3 also showed a greater tendency to concentrate in the nucleus, where it colocalized with the proteasome in subnuclear foci. Taken together, these and other findings suggest that the catalytic activity of this disease-linked deubiquitinating enzyme regulates several of its cellular properties, which in turn may influence disease pathogenesis.

10 August 2022 in Redox Biology
Verified
Journal Article
Open access
Carla LopesCarla Lopes
Carla Lopes
IFIldete Luísa Ferreira
Ildete Luísa Ferreira
CMCarina Maranga
Carina Maranga
MBMargarida Beatriz
Margarida Beatriz
Sandra MotaSandra Mota
Sandra Mota
Ana Cristina Cristina RegoAna Cristina Cristina Rego
Ana Cristina Cristina Rego
Deficits in mitochondrial function and redox deregulation have been attributed to Huntington's disease (HD), a genetic neurodegenerative disorder largely affecting the striatum. However, whether these changes occur in early stages of the disease and can be detected in vivo is still unclear. In the present study, we analysed changes in mitochondrial function and production of reactive oxygen species (ROS) at early stages and with disease progression. Studies were performed in vivo in human brain by PET using [64Cu]-ATSM and ex vivo in human skin fibroblasts of premanifest and prodromal (Pre-M) and manifest HD carriers. In vivo brain [64Cu]-ATSM PET in YAC128 transgenic mouse and striatal and cortical isolated mitochondria were assessed at presymptomatic (3 month-old, mo) and symptomatic (6–12 mo) stages. Pre-M HD carriers exhibited enhanced whole-brain (with exception of caudate) [64Cu]-ATSM labelling, correlating with CAG repeat number. Fibroblasts from Pre-M showed enhanced basal and maximal respiration, proton leak and increased hydrogen peroxide (H2O2) levels, later progressing in manifest HD. Mitochondria from fibroblasts of Pre-M HD carriers also showed reduced circularity, while higher number of mitochondrial DNA copies correlated with maximal respiratory capacity. In vivo animal PET analysis showed increased accumulation of [64Cu]-ATSM in YAC128 mouse striatum. YAC128 mouse (at 3 months) striatal isolated mitochondria exhibited a rise in basal and maximal mitochondrial respiration and in ATP production, and increased complex II and III activities. YAC128 mouse striatal mitochondria also showed enhanced mitochondrial H2O2 levels and circularity, revealed by brain ultrastructure analysis, and defects in Ca2+ handling, supporting increased striatal susceptibility. Data demonstrate both human and mouse mitochondrial overactivity and altered morphology at early HD stages, facilitating redox unbalance, the latter progressing with manifest disease.